PlumX Metrics
Embed PlumX Metrics

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis

Annals of the Rheumatic Diseases, ISSN: 0003-4967, Vol: 81, Issue: 3, Page: 321-326
2022
  • 175
    Citations
  • 0
    Usage
  • 106
    Captures
  • 3
    Mentions
  • 15
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    175
  • Captures
    106
  • Mentions
    3
    • References
      2
      • Wikipedia
        2
    • News Mentions
      1
      • News
        1
  • Social Media
    15
    • Shares, Likes & Comments
      15
      • Facebook
        15

Most Recent News

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Carlo Mümmler,1 Pontus Mertsch,1 Michaela Barnikel,1 Frank Haubner,2 Ulf Schönermarck,3 Ulrich Grabmaier,4 Hendrik Schulze-Koops,5 Jürgen Behr,1 Nikolaus Kneidinger,1,6 Katrin Milger1 1Department of Medicine V, LMU

Article Description

To develop and validate classification criteria for microscopic polyangiitis (MPA). Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. The development set for MPA consisted of 149 cases of MPA and 408 comparators. The validation set consisted of an additional 142 cases of MPA and 414 comparators. From 91 candidate items, regression analysis identified 10 items for MPA, 6 of which were retained. The final criteria and their weights were as follows: perinuclear antineutrophil cytoplasmic antibody (ANCA) or anti-myeloperoxidase-ANCA positivity (+6), pauci-immune glomerulonephritis (+3), lung fibrosis or interstitial lung disease (+3), sino-nasal symptoms or signs (−3), cytoplasmic ANCA or anti-proteinase 3 ANCA positivity (−1) and eosinophil count ≥1×10 9 /L (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having MPA with a cumulative score of ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 91% (95% CI 85% to 95%) and the specificity was 94% (95% CI 92% to 96%). The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for MPA are now validated for use in clinical research.

Bibliographic Details

Ravi Suppiah; Joanna C Robson; Peter C Grayson; Cristina Ponte; Anthea Craven; Sara Khalid; Andrew Judge; Andrew Hutchings; Peter A Merkel; Raashid A Luqmani; Richard A Watts; Paul Gatenby; Catherine Hill; Dwarakanathan Ranganathan; Andreas Kronbichler; Daniel Blockmans; Lillian Barra; Simon Carette; Christian Pagnoux; Navjot Dhindsa; Aurore Fifi-Mah; Nader Khalidi; Patrick Liang; Nataliya Milman; Christian Pineau; Xinping Tian; Guochun Wang; Tian Wang; Ming-hui Zhao; Vladimir Tesar; Bo Baslund; Nevin Hammam; Amira Shahin; Laura Pirila; Jukka Putaala; Bernhard Hellmich; Jörg Henes; Peter Lamprecht; Thomas Neumann; Wolfgang Schmidt; Cord Sunderkoetter; Zoltan Szekanecz; Debashish Danda; Siddharth Das; Rajiva Gupta; Liza Rajasekhar; Aman Sharma; Shrikant Wagh; Michael Clarkson; Eamonn Molloy; Carlo Salvarani; Franco Schiavon; Enrico Tombetti; Augusto Vaglio; Koichi Amano; Yoshihiro Arimura; Hiroaki Dobashi; Shouichi Fujimoto; Masayoshi Harigai; Fumio Hirano; Junichi Hirahashi; Sakae Honma; Tamihiro Kawakami; Shigeto Kobayashi; Hajime Kono; Hirofumi Makino; Kazuo Matsui; Eri Muso; Kazuo Suzuki; Kei Ikeda; Tsutomu Takeuchi; Tatsuo Tsukamoto; Shunya Uchida; Takashi Wada; Hidehiro Yamada; Kunihiro Yamagata; Wako Yumura; Kan Sow Lai; Luis Felipe Flores-Suarez; Andrea Hinojosa; Bram Rutgers; Paul-Peter Tak; Rebecca Grainger; Vicki Quincey; Lisa Stamp; Emilio Besada; Andreas Diamantopoulos; Jan Sznajd; Elsa Azevedo; Ruth Geraldes; Miguel Rodrigues; Ernestina Santos; Yeong-Wook Song; Sergey Moiseev; Alojzija Hocˇevar; Maria Cinta Cid; Xavier Solanich Moreno; Inoshi Atukorala; Ewa Berglin; Aladdin Mohammed; Mårten Segelmark; Thomas Daikeler; Haner Direskeneli; Gulen Hatemi; Sevil Kamali; Ömer Karadag; Seval Pehlevan; Matthew Adler; Neil Basu; Iain Bruce; Kuntal Chakravarty; Bhaskar Dasgupta; Oliver Flossmann; Nagui Gendi; Alaa Hassan; Rachel Hoyles; David Jayne; Colin Jones; Rainer Klocke; Peter Lanyon; Cathy Laversuch; Raashid Luqmani; Joanna Robson; Malgorzata Magliano; Justin Mason; Win Win Maw; Iain McInnes; John Mclaren; Matthew Morgan; Ann Morgan; Chetan Mukhtyar; Edmond O'Riordan; Sanjeev Patel; Adrian Peall; Srinivasan Venkatachalam; Erin Vermaak; Ajit Menon; Richard Watts; Chee-Seng Yee; Daniel Albert; Leonard Calabrese; Sharon Chung; Lindsy Forbess; Angelo Gaffo; Ora Gewurz-Singer; Peter Grayson; Kimberly Liang; Eric Matteson; Peter A. Merkel; Jason Springer; Antoine Sreih

Elsevier BV

Medicine; Immunology and Microbiology; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know